DOCSLIB.ORG

Author Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Author Index Author Index Page numbers in italics refer to bibliography Abdullah S, Miller OJ 243, 253 Ackenheil M, see Riither E Aghajanian GK, see Baraban Abdullah YH, Hamadah K 219,222 JM 145,152 480, 484, 493, 500 Ackenheil M, see Schilkrut R Aghajanian GK, see Bunney Aber RC, see Forrest IS 245, 219,223 BS 101, 105, 127, 133, 134, 257 Ackenheil M, see Stralendorff B 141,154,155, 194, 195, 199, Abood LG, see Meduna LJ von 101,110 205,207 450, 469 Ackenheil M, see Zander K-J Aghajanian GK, see Graham Abood LG, see Walaszek EJ 216,223 AW 142,143,160 68,88 Ackenheil M, see Zimmer R Aghajanian GK, see Montigny Abraham R, Hendy R, Grasso 220,223 C de 521,522 P 537,544 Adachi M, see Volk BW 537, Aghajanian GK, see Nybiick Abraham RJ, Kricka LJ, 549 HV 422,432,474,477,487 Ledwith A 355, 357, 362 Adam HM, Hye HKA 46, 52 Aghajanian GK, see Roth RH Abraham RJ, Lewtas K, Adams AE, Fudge MW 252, 197, 211 Thomas W A 355, 362 253 Aghajanian GK, see Sheard Abrams GD, see Bree MM Adams E, see Mashiter K 343, MH 422, 433, 476, 488 237,254 347 Aghajanian GK, see Svensson Abramson HA, Evans L T 68, Adams HR 248, 253 TH 143,172 81 Adams HR, Manian AA, Aghajanian K, see Bunney BS Adbal E, Subini S, Spatz J, Steenberg ML, Buckley JP 422, 429 Falent R, Merzberger B, 245,253 Agid Y, Guyenet PG, Glowinski Gales A, Moizeszowicz J Adams HR, Smookler HH, J, Beaujouan JC, Javoy F 359, 362 Clarke DE, Jandhyala BS, 128, 150, 197,206 Aceto MD 604, 606, 607, 618 Dixit BN, Ertel RJ, Buckley Agid Y, see Guyenet PG 128, Ackenheil A, see Matussek N jp 49,52 216, 217, 222 Adamsons K, see Towell ME 160, 197,202,208 Ackenheil M 220, 220 249, 264 Agid Y, see Javoy F 198, 199, Ackenheil M, Beckmann H, Adelstein AM, see Greenberg 209 Agid Y, see Javoy P 135, 162 Greil W, Hoffmann C, G 538, 546 Markianos E, Raese J 216, Adler M, see Gessner PK 529, Agidy Y, see Guyenet PG 128, 219,220 546 160 Ackenheil M, Beckmann H, Adlerova E, see Pelz K 14, 24 Agnati L, see Fuxe K 202, 208 Hoffmann G, Markianos E, Adrian RW, see Schatz F 566, Ahlenius S 47,48, 52 Nystrom I, Raese J 215,220 572 Ahlenius S, Anden N-E, Engel Ackenheil M, Brau H, Burkhart Aeppli L 539, 544 J 47,52 A, Franke A, Pacha W 277, Aeppli L, see Stenger EG 539, Ahlenius S, Brown R, Engel J, 278 548 Lundborg P 232, 253 Ackenheil M, Hippius H 277, Agedal 355, 363 Ahlenius S, EngelJ 47,52,103, 278 Aghajanian GK, Bloom FE 104 Ackenheil M, Hippius H, 407, 410 Ahlenius S, see Engel J 232, Matussek N 59, 80, 81 Aghajanian GK, Bunney BS 256 Ackenheil M, see Eben E 215, 127, 135, 150, 183, 190, 199, Ahlfors UG, see Jaskari MO 219,221 205 362,365 Ackenheil M, see Naber D Aghajanian GK, Graham MH, Ahlman H, Grillner S, Udo M 216, 218, 222 Sheard MH 427, 428 119,150 624 Author Index Ahn HS, Gardner E, Makman Alfredsson G, Wiesel F-A, Skett Amdisen A, see Schou M 341, MH 144,150 P 287, 291, 299 348, 584, 587, 589 Ahtee L, Saarnivara L 474,484 Alfredsson G, Woge-Helgodt B, Amenomori Y, see Lu K-H Aichinger G, Behner 0, Sedvall G 268,269,278 144, 166, 252, 260 Hoffmeister F, Schutz S Alfredsson G, see Sedvall G Amores GY, see Fromm GH 355,363 219, 220, 223 444,467 Airoldi L, Marcucci F, Mussini Algeri EJ, Ratsas GG, McBay Amundson ME, Manthey JA E, Garattini S 298, 298 AJ 242,253 562,567 Airoldi L, see Marcucci F 277, Ali N, see McClelland HA 201, Anagnoste B, see Goldstein M 282 210 127, 147, 159, 160 Aizenshtat Z, Klein E, Weiler­ Allaye R, see Davies DM 448, Anand BK, see Manchanda Feilchenfeld H, Bergmann 466 SK 426, 427, 432 ED 5,20 Allegranza A, see Bruno A Ananth J 243, 253, 544 215,221 Akera T, Brody TM 290,298 Ananth I, Luchins D 384,393 Allen BS, see Allen G 48, 52 Akera T, see Lee C-Y 124,165 Ananth J, Valles JV, Whitelaw Allen G, Allen BS, Rake AV Akpinar S, see Hil TM 453, IP 246,253 48,52 464, 465, 467, 468 Andel H van, see Ernst AM 73, Allen GS, Rand MJ 528, 544 AH 83 Al-Sarraj S, see Beckett Allewijn F, see Soudijn W 298, 553, 562, 567 Andlm N-E 117,134,151,193, 303 194,202,206 Al-Shaltchi B, see Fleischhauer Allewijn FTN, see Janssen J 507,522 Anden N-E, Bedard P 132, PAJ 113, 162,298,301 151, 198,206 Alanen YO, Eberhard G, Gerle Allewijn FTN, see Lewi PJ BO, Hansson B, Rosman C, Anden N-E, Butcher SG, 298,302 Corrodi H, Fuxe K, Sedvall G 103, 104 Allgen L-G, Jorisson B, UngerstedtU 112,117,127, Alani MD 245, 253 Nauckhoff B, Andersen M­ 132, 151, 202, 206 Alani MD, Dunne JH 245,253 L, Huus I, Meller Nielsen I Albala BJ, see Palfai T 48,56 290,299 Anden N-E, Carlsson A, Albe-Fessard D, see Feltz P Alltop LB, see Prange AJ Jr. Dahlstrom A, Fuxe K, 129,158 458,469 Hillarp N-A, Larsson K Alberici M, see Robertis E de Alluaume R, see Laborit H 111, 115-117, 119, 127, 131, 145, 158 234,259 136,151 Albert J-M, see Cooper SF Alluisi EA, see Loeb M 321, Andim N-E, Carlsson A, Hillarp 269, 274, 279 334 N-A, Magnusson T 111, Albiero L, see Tofanetti °533, Almazova IG 242, 253 115-117, 119, 127, 131, 136, 549 Almond CH, see Boulos BM 151 Alcalay R, see Lecompte G 241,254 Anden N-E, Corrodi H, Fuxe 574,582 Alstaedter A, see ZipfHF 235, K 118, 132, 152 Aldrige V, see Walter-Grey W 237,265 Anden N-E, Corrodi H, Fuxe 187, 192 Altman N, see Sachar EJ 216, K, Hokfelt B, Hokfelt T, Alexander FW, see Sykes PA 218,223 Rydin C, Svensson T 112, 587,589 Alton H, see Goodall Mc C 117, 127, 132,151,518,521 Alexander GJ, Machiz S, 492,502 Anden N-E, Corrodi H, Fuxe Alexander RB 240,241,253 Alvan G, Borga 0, Lind M, K, Hokfelt T 111, 112, 115, Alexander L 313, 327,332, Palmer L, Siwers B 563, 567 151 575,581 Amadeo M, see Shagass C 575, Anden N-E, Corrodi H, Fuxe Alexander RB, see Alexander 582 K, Ungerstedt U 132, 152 GJ 240, 241, 253 Amano Y, see Takaori S 126, Anden N-E, Dahlstrom A, Fuxe Alexander SF, see Kline NS 143, 172 K, Larsson K 75,81,117, 391,395 Amarger J, see Kehl R 249, 121, 127, 136, 144, 151 Alexanderson B 556, 567 250,259 Anden N-E, Dahlstrom A, Fuxe Alexanderson B, Borga ° 563, AmdisenA 583,584,587 K, Olson L, Ungerstedt U 567 Amdisen A, Schou M 587,587 121, 143, 144, 151 Alexanderson B, see Bertilsson Amdisen A, see Hansen HE Anden N-E, Engel J, Rubenson L 562,567 584, 585, 588 A 118, 132, 152 Alexanderson B, see Hammar Amdisen A, see Hestbech J Anden N-E, Fuxe K, Hokfelt C-G 561, 562,570 586,588 TIll, 112, 115, 151 Author Index 625 Anden N-E, Fuxe K, Larsson Anderson EG, see Baker RG Anlezark GM, Meldrum BS K 76,81 116, 117, 152 125, 152 Anden N-E, Hiiggendal J, Anderson H, Ross BE 496, 500 Anlezark GM, see Meldrum Magnusson T, Rosengren E Anderson MS, see Plotnikoff BS 227,233,261 Ill, 115-117, 119, 127, 131, NP 515,524 Anman WHW, see Greenberg 136, 151 Anderson PS, see Remy DC 7, G 538, 546 And(m N-E, Jukes MGM, 12,25, 357, 366 Annable L, see Chouinard G Lundberg A 50, 52, 111, Anderson RC, see Meyers DB 37, 38, 278, 278 115-117, 119, 127, 131, 136, 530, 532, 547 Ansoms G, Backer-Dierick G 151 Anderson Th R, see Bartolome de, Vereecken JLTM 36,37 Anden N-E, Jukes MGM, J 250,253 Antilla M, see Linnoila M 273, Lundberg A, Vyklicky L Andersson S, see Sjoqvist F 282 116, 143, 151 558,572 Anton AH, Sayre DF 115, 152 Anden N-E, Lundberg A, Ando F, see Itoh T 238,240, Antonaccio MJ, Smith CB 45, Rosengren E, Vyklicky L 258 52 116, 151 Andreola ML, see Cazzullo Antonchak N, see Gaunt R Anden N-E, Magnusson T, CL 245, 252, 255 249,252,257 Waldeck B 111,115-117, Angelini F, see Raiteri M 362, Apfelbach R, see Schmidt W 119, 127, 131, 151 366 70,86 Anden N-E, Roos B-E, Anggard E, Gunne L-M, Apgar V 243,251,253 Werdenius Bill, 115-117, Jonsson LE, Niklasson F Applegate CW, see Schildkraut 119, 127, 131, 136, 151, 218, 99,104 JJ 479,488 221 Anggard E, see Sjoqvist B 218, Appleton WS, Shader RI, Anden N-E, Rubenson A, Fuxe 223 DiMascio A 245, 253 K, Hokfelt T 75, 81, 111, Angrist BM, Gershon S 98, 99, Argenta G, see Jori A 498,502 112, 115, 151 104 Anden N-E, Stock G 140,151, Angrist BM, Lee HK, Gershon Arias L, see Mitchell JR 478, 199, 204, 206 S 99,104 487 Anden N-E, Strombom U, Angrist BM, Rotrosen J, Arieff AI, Friedman EA 242, Svensson T 47, 52 Aronson M, Gershon S 13, 253 Arieff AI, see Simon NM 586, Anden N-E, Strombom U, 20 589 Svensson TH 517,521 Angrist BM, Sathananthan G, Arison BH, see Hucker HB Anden N-E, Wachtel H 202, Wilk S, Gershon S 98, 99, 353,365, 561, 562, 564, 570 206 104, 142, 152 Anden N-E, see Ahlenius S 47, Angrist BM, Schweitzer J, Arison BH, see Remy DC 7, 52 Friedhoff AI, Gershon S, 12,25 Anden N-E, see Jackson DM Hekimian LJ, Floyd A 99, Armitage GH, see Sim M 36, 200,203,208 104 40 Armstrong B, Stevens N, Doll Andeo N-E, see Meek JL 424, Angrist BM, Sudilovsky A 98, R 340,346 432, 476, 487 99,104 Anden N-E, see Ungerstedt U Angrist BM, see Rotrosen J Amaiz G, see Robertis E de 136,173 216, 217, 222 145, 158 Andermann K, Fink M 574, Angst J, Battegay R, Bente D, Arnould F, see Paquay J 35, 581 Berner P, Broeren W, Cornu 36,40 Andersen H, Braestrup C 99, F, Dick P, Engelmeier MP, Arnt J, see Scheel-Kruger J 97, 104 Heimann H, Heinrich K, 109 Andersen H, Braestrup C, Helmchen H, Hippius H, Aroney MJ, Cleaver G, Fevre RandrupA 97,100,104 POldinger W, Schmidlin P, RJW Le, Pierens RK 5, 20 Andersen H, see Braestrup C Schmitt W, Weis P 60, 81 Aronson M, see Angrist BM 472,484 Angst J, Gram LF 102,104 13,20 Andersen M-L, see Allgen L-G Angst J, POldinger W 36,37 Arrigoni-Martelli E, Kramer 290,299 Angwin P, see Siever L 496, M 594, 596,600,601,618 Anderson EG 50,52 504 Artelli A, Castello A 245, 253 Anderson EG, Haas H, Hosli Anlezak G, see Trimble M 417, Arushanian EB, Avakian RM L 149,152 434 592, 600, 601, 618 Anderson EG, Holgerson LO Anlezark G, Pycock G, Arvidsson J, Jurna I, Steg G 115, 152 Meldrum.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Formulary (List of Covered Drugs)
    3ODQ<HDU 202 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THE FOLLOWING PLAN: $0 Cost Share AI/AN HMO Minimum Coverage HMO Silver 70 HMO Active Choice PPO Silver Opal 25 Gold HMO Silver 70 OFF Exchange HMO Amber 50 HMO Silver Opal 50 Silver HMO Silver 73 HMO Bronze 60 HDHP HMO Platinum 90 HMO Silver 87 HMO Bronze 60 HMO Ruby 10 Platinum HMO Silver 94 HMO Gold 80 HMO Ruby 20 Platinum HMO Jade 15 HMO Ruby 40 Platinum HMO This formulary was last updated on8//20. This formulary is VXEMHFWto change and all previous versions of the formulary no longer apply. For more recent information or other questions, please contact Chinese Community Health Plan Member Services at 1-888-775-7888 or, for TTY users, 1-877-681-8898, seven days a week from 8:00 a.m. to 8:00 p.m., or visit www.cchphealthplan.com/family-member -,-ϭ -,-ϭ"&* !#" + 5 5 ),-$+" %(%'.')/"+#" %&/"+ -%/"$)% "%&/"+ *& )&! %&/"+ 0 $(#" '"+ %&/"+ *& %&/"+ %&/"+ +)(2" &-%(.' %&/"+ +)(2" .1&-%(.' %&/"+ )&! .1&-%(.' !" .1&-%(.' dŚŝƐĨŽƌŵƵůĂƌLJǁĂƐůĂƐƚƵƉĚĂƚĞĚ8ͬϭͬϮϬϮϭ͘dŚŝƐĨŽƌŵƵůĂƌLJŝƐƐƵďũĞĐƚƚŽ ĐŚĂŶŐĞĂŶĚĂůůƉƌĞǀŝŽƵƐǀĞƌƐŝŽŶƐŽĨƚŚĞĨŽƌŵƵůĂƌLJŶŽůŽŶŐĞƌĂƉƉůLJ͘&ŽƌŵŽƌĞ ƌĞĐĞŶƚŝŶĨŽƌŵĂƚŝŽŶŽƌŽƚŚĞƌƋƵĞƐƚŝŽŶƐ͕ƉůĞĂƐĞĐŽŶƚĂĐƚŚŝŶĞƐĞŽŵŵƵŶŝƚLJ ,ĞĂůƚŚWůĂŶDĞŵďĞƌ^ĞƌǀŝĐĞƐĂƚϭͲϴϴϴͲϳϳϱͲϳϴϴϴŽƌ͕ĨŽƌddzƵƐĞƌƐ͕ ϭͲϴϳϳͲϲϴϭͲϴϴϵϴ͕ƐĞǀĞŶĚĂLJƐĂǁĞĞŬĨƌŽŵϴ͗ϬϬĂ͘ŵ͘ƚŽϴ͗ϬϬƉ͘ŵ͕͘ŽƌǀŝƐŝƚ ǁǁǁ͘ĐĐŚƉŚĞĂůƚŚƉůĂŶ͘ĐŽŵͬĨĂŵŝůLJͲŵĞŵďĞƌ !! %+)&,+ &%+&+&)$,#)0),# *+666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I % + &%*6666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666666I
    [Show full text]
  • Antipsychotics (Part-4) FLUOROBUTYROPHENONES
    Antipsychotics (Part-4) FLUOROBUTYROPHENONES The fluorobutyrophenones belong to a much-studied class of compounds, with many compounds possessing high antipsychotic activity. They were obtained by structure variation of the analgesic drug meperidine by substitution of the N-methyl by butyrophenone moiety to produce the butyrophenone analogue which has similar activity as chlorpromazine. COOC2H5 N H3C Meperidine COOC2H5 N O Butyrophenone analog The structural requirements for antipsychotic activity in the group are well worked out. General features are expressed in the following structure. F AR Y O N • Optimal activity is seen when with an aromatic with p-fluoro substituent • When CO is attached with p-fluoroaryl gives optimal activity is seen, although other groups, C(H)OH and aryl, also give good activity. • When 3 carbons distance separates the CO from cyclic N gives optimal activity. • The aliphatic amino nitrogen is required, and highest activity is seen when it is incorporated into a cyclic form. • AR is an aromatic ring and is needed. It should be attached directly to the 4-position or occasionally separated from it by one intervening atom. • The Y group can vary and assist activity. An example is the hydroxyl group of haloperidol. The empirical SARs suggest that the 4-aryl piperidino moiety is superimposable on the 2-- phenylethylamino moiety of dopamine and, accordingly, could promote affinity for D2 receptors. The long N-alkyl substituent could help promote affinity and produce antagonistic activity. Some members of the class are extremely potent antipsychotic agents and D2 receptor antagonists. The EPS are extremely marked in some members of this class, which may, in part, be due to a potent DA block in the striatum and almost no compensatory striatal anticholinergic block.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor
    Gastroenterology 2020;158:1433–1449 Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice Prasad Dandawate,1 Gaurav Kaushik,2 Chandrayee Ghosh,1 David Standing,1 Afreen Asif Ali Sayed,1 Sonali Choudhury,1 Dharmalingam Subramaniam,1 Ann Manzardo,3 Tuhina Banerjee,4 Santimukul Santra,4 Prabhu Ramamoorthy,1 Merlin Butler,3 Subhash B. Padhye,1,5 Joaquina Baranda,6 Anup Kasi,6 Weijing Sun,6 Ossama Tawfik,7 Domenico Coppola,8 Mokenge Malafa,8 Shahid Umar,2 Michael J. Soares,7,9,10,11 Subhrajit Saha,12 Scott J. Weir,1,13 Animesh Dhar,1 Roy A. Jensen,1,7 Sufi Mary Thomas,1,14 and Shrikant Anant1,2,5 1Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas; 2Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas; 3Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, Kansas; 4Department of Chemistry, Pittsburg State University, Pittsburg, Kansas; 5Interdisciplinary Science and Technology Research Academy, Abeda Inamdar College, University of Pune, Pune; 6Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas; 7Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; 8Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida; 9Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, Kansas; 10Department
    [Show full text]
  • Depression and Structural Factors Are Associated with Symptoms in Patients of Irritable Bowel Syndrome with Diarrhea
    J Neurogastroenterol Motil, Vol. 26 No. 4 October, 2020 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm19166 JNM Journal of Neurogastroenterology and Motility Original Article Depression and Structural Factors Are Associated With Symptoms in Patients of Irritable Bowel Syndrome With Diarrhea Jia Lu,1 Lili Shi,2 Dan Huang,3 Wenjuan Fan,1 Xiaoqing Li,1 Liming Zhu,1 Jing Wei,2 and Xiucai Fang1* Departments of 1Gastroenterology and 2Psychological Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and 3Department of Gastroenterology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China Background/Aims A strong correlation between depression and irritable bowel syndrome with diarrhea (IBS-D) has been identified. The aim of this study is to identify the correlations among depression, structural factors, gastrointestinal (GI) and extra-GI symptoms, and efficacy of neuromodulators in patients with IBS-D. Methods Patients meeting the Rome III Diagnostic Criteria for IBS-D were enrolled. The intestinal symptoms and psychological states were evaluated using IBS-specific symptom questionnaires and Hamilton Depression Rating Scale. Results In total, 410 patients with IBS-D were enrolled, 28.8% (118/410) had comorbid depression. Patients with depression did not readily experience improvement in abdominal pain/discomfort after defecation, and had a higher prevalence of passing mucus, overlapping functional dyspepsia, and extra-GI symptoms. The structural factor “mental disorders” significantly correlated with main bowel symptom score and degree of pre-defecation abdominal pain/discomfort. No structural factor significantly correlated with bowel movements or stool form.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • 9719087.Pdf (3.190Mb)
    US009719087B2 a2) United States Patent (0) Patent No.: US 9,719,087 B2 Olson et al. (45) Date of Patent: *Aug. 1, 2017 (54) MICRO-RNA FAMILY THAT MODULATES A61LK 39/3955 (2013.01); AGLK 45/06 FIBROSIS AND USES THEREOF (2013.01); A6IL 31/08 (2013.01); AGIL 31/16 (2013.01); C12N 9/16 (2013.01); C12N (71) Applicant: THE BOARD OF REGENTS, THE 15/8509 (2013.01); AOIK 2207/30 (2013.01); UNIVERSITY OF TEXAS SYSTEM, AOIK 2217/052 (2013.01); AOLK 2217/075 Austin, TX (US) (2013.01); AOIK 2217/15 (2013.01); AOIK 2217/206 (2013.01); AOIK 2227/105 (72) Inventors: Erie N. Olson, Dallas, TX (US); Eva (2013.01); AOIK 2267/0375 (2013.01); AIL van Rooij, Utrecht (NL) 2300/258 (2013.01); A6IL 2300/45 (2013.01); : AOIL 2420/06 (2013.01); C12N 2310/113 (73) Assignee: THE BOARD OF REGENTS, THE (2013.01); CI2N 2310/141 (2013.01); CI2N UNIVERSITY OF TEXAS SYSTEM, 2310/315 (2013.01); C12N 2310/321 Austin, TX (US) (2013.01); C12N 2310/346 (2013.01); C12N (*) Notice: Subjectto any disclaimer, the termbe this (013.01ars orb01301CDN US.C.patent154(b)is extendedby 0 ordays.adjusted under 2320/32 (2013.01);4 . CI2N 2330/10yor(2013.01) (58) Field of Classification Search This patent is subject to a terminal dis- CPC vieceeceseeseeeeeeee C12N 15/113; C12N 2310/141 claimer. See application file for complete search history. — (21) Appl. No.: 14/592,699 (56) References Cited (22) Filed: Jan. 8, 2015 U.S. PATENT DOCUMENTS (65) Prior Publication Data 7,232,806 B2 6/2007 Tuschlet al.
    [Show full text]